{
    "nctId": "NCT01517802",
    "briefTitle": "A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate",
    "officialTitle": "A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 32,
    "primaryOutcomeMeasure": "Number of Participants With Serious Adverse Events (SAEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Currently participating in an abiraterone acetate clinical study considered complete and had received at least 3 months of treatment with abiraterone acetate tablets.\n\nExclusion Criteria:\n\n* Medical conditions that require hospitalization.\n* Any condition or situation which, in the opinion of the investigator, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study.",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}